StruckJ, MorgenthalerNG, BergmannA. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides2005;26:2500–4.doi:10.1016/j.peptides.2005.04.019
2.
OdermattJ, BolligerR, HersbergerL, . Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study. Clin Chem Lab Med2016;54:1681–90.doi:10.1515/cclm-2016-0151
3.
KatanM, FluriF, MorgenthalerNG, . Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol2009;66:799–808.doi:10.1002/ana.21783
4.
KhanSQ, DhillonOS, O'BrienRJ, . C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation2007;115:2103–10.doi:10.1161/CIRCULATIONAHA.106.685503
5.
MüllerB, MorgenthalerN, StolzD, . Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest2007;37:145–52.doi:10.1111/j.1365-2362.2007.01762.x
6.
AhmedAB, GeorgeBC, Gonzalez-AuvertC, . Increased plasma arginine vasopressin in clinical adrenocortical insufficeincy and its inhibition by glucosteroids. J Clin Invest1967;46:111–23.doi:10.1172/JCI105504
7.
ErkutZA, PoolC, SwaabDF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab1998;83:2066–73.doi:10.1210/jc.83.6.2066
8.
de KruifMD, LemaireLC, GiebelenIA, . The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med2008;34:518–22.doi:10.1007/s00134-007-0955-x
9.
BlumCA, NigroN, BrielM, . Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet2015;385:1511–8.doi:10.1016/S0140-6736(14)62447-8
